Utilisation of Novel Contrast Agents in Studies of Type 1 and Type 2 Diabetes

Utilisation of Novel Contrast Agents in Studies of Type 1 and Type 2 Diabetes

Manganese (Mn2+) is taken up in beta cells of islets via voltage-gated calcium channels. Since both Type 1 and Type 2 diabetes are characterised by diminished numbers and activity of beta cells, non-invasive detection of beta cells with manganese compounds may allow monitoring of treatment or disease progression. The contrast agent manganese gluconate is licensed in man and working with the Clinical Research Imaging Centre, we have demonstrated its utility in a rat model. In these studies, rats were administered 50% dextrose (2ml/kg) and enhancement of the liver was compared to enhancement in the pancreas following the administration of the contrast agent. Our subsequent studies will explore the utility in man in longitudinal studies.

 

Collaborators: University of Edinburgh – Edinburgh Imaging, GlaxoSmithKline

Team members involved in this programme: Lucy Elizabeth Kershaw, David Lilburn, Andrew Bond, Salamah Alwahsh, Maurits Jansen, Pilar Jimenez-Royo, Antonella Napolitano Rosen, Philip Murphy, Alexandra Morgan, Rob Janiczek